Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Invested Capital (2020 - 2023)

Historic Invested Capital for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $468.8 million.

  • Cullinan Therapeutics' Invested Capital fell 2001.46% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 2001.46%. This contributed to the annual value of $535.0 million for FY2022, which is 2577.85% up from last year.
  • Latest data reveals that Cullinan Therapeutics reported Invested Capital of $468.8 million as of Q3 2023, which was down 2001.46% from $499.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' 5-year Invested Capital high stood at $604.6 million for Q2 2022, and its period low was $200.3 million during Q4 2020.
  • In the last 4 years, Cullinan Therapeutics' Invested Capital had a median value of $469.3 million in 2021 and averaged $466.6 million.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 11235.36% in 2021, then crashed by 2001.46% in 2023.
  • Quarter analysis of 4 years shows Cullinan Therapeutics' Invested Capital stood at $200.3 million in 2020, then soared by 112.35% to $425.4 million in 2021, then rose by 25.78% to $535.0 million in 2022, then dropped by 12.38% to $468.8 million in 2023.
  • Its Invested Capital was $468.8 million in Q3 2023, compared to $499.6 million in Q2 2023 and $485.6 million in Q1 2023.